139 related articles for article (PubMed ID: 2526214)
1. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist.
Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA
J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214
[TBL] [Abstract][Full Text] [Related]
2. Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats.
Fuller RW; Hemrick-Luecke SK; Wong DT; Pearson D; Threlkeld PG; Hynes MD
J Pharmacol Exp Ther; 1983 Nov; 227(2):354-9. PubMed ID: 6138425
[TBL] [Abstract][Full Text] [Related]
3. Effects of the selective dopaminergic D2 agonist quinelorane on the activity of dopaminergic and noradrenergic neurons projecting to the diencephalon of the rat.
Eaton MJ; Lookingland KJ; Moore KE
J Pharmacol Exp Ther; 1994 Feb; 268(2):645-52. PubMed ID: 7906734
[TBL] [Abstract][Full Text] [Related]
4. Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging.
Ireland MD; Lowe AS; Reavill C; James MF; Leslie RA; Williams SC
Neuroscience; 2005; 133(1):315-26. PubMed ID: 15893653
[TBL] [Abstract][Full Text] [Related]
5. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Fuller RW; Clemens JA; Hynes MD
J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
[TBL] [Abstract][Full Text] [Related]
6. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.
Robertson GS; Tham CS; Wilson C; Jakubovic A; Fibiger HC
J Pharmacol Exp Ther; 1993 Mar; 264(3):1344-51. PubMed ID: 8095550
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
Imperato A; Tanda G; Frau R; Di Chiara G
J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
9. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
Gackenheimer SL; Schaus JM; Gehlert DR
J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
Clemens JA; Okimura T; Smalstig EB
Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
12. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
DeBoer P; Abercrombie ED
J Pharmacol Exp Ther; 1996 May; 277(2):775-83. PubMed ID: 8627558
[TBL] [Abstract][Full Text] [Related]
13. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
Jeziorski M; White FJ
Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel antagonist isradipine attenuates cocaine-induced motor activity in rats: correlation with brain monoamine levels.
Mills K; Arsah TA; Ali SF; Shockley DC
Ann N Y Acad Sci; 1998 May; 844():201-7. PubMed ID: 9668678
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
17. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
18. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of the dopamine D2 agonist quinelorane on tuberoinfundibular dopaminergic neuronal activity in male and female rats.
Eaton MJ; Gopalan C; Kim E; Lookingland KJ; Moore KE
Brain Res; 1993 Nov; 629(1):53-8. PubMed ID: 7904532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
